Norgine, a leading European speciality pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated pharma & life sciences company of India, announced today, that they have entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilising Jubilant Biosys integrated drug discovery platform targeting gastrointestinal diseases.
Under the terms of the agreement Jubilant shall deliver preclinical candidates to Norgine who will own all rights to further development and commercialisation of the candidates.
Commenting on the collaboration, Sri Mosur, President and CEO, Global Drug Discovery and Development at Jubilant said: “Jubilant is very pleased to partner with Norgine, a very successful European speciality pharmaceutical company. We are confident our “accelerated discovery” platform will enable Norgine’s quest for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and worldwide in the area of gastrointestinal disease”.
